Tozorakimab for Uncontrolled Asthma Study
This study is testing a drug called tozorakimab to see how well it works and if it's safe for adults with asthma that isn't well-controlled by their current medications. You might be able to join if you are between 18 and 75 years old, have had asthma for at least a year, and are currently taking medium-to-high dose inhaled corticosteroids (steroid medications you breathe in) along with a LABA (long-acting bronchodilator). The main goal is to see if tozorakimab can reduce the number of severe asthma attacks you have over 26 to 52 weeks. This study is currently unclear about its recruitment status and plans to enroll 540 participants.
- Study design
- This is a Phase IIb, dose-range finding study that is double-blind and placebo-controlled. It plans to enroll 540 adult participants.
- What's involved
- You would receive either tozorakimab or a placebo (an inactive substance) given as an injection under the skin.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint for measuring severe asthma exacerbations is over 26 to 52 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
At a glance
Conditions
Where it's being run
221 sites across 46 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Annualised rate of severe asthma exacerbationsOver 26 to 52 weeks
The rate ratio of severe asthma exacerbations will be assessed in the participants with uncontrolled moderate-to-severe asthma and ≥ 1 severe exacerbation within 12 months prior to screening.